News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
854,069 Results
Type
Article (86980)
Company Profile (704)
Press Release (766384)
Multimedia
Podcasts (152)
Webinars (19)
Section
Business (232868)
Career Advice (4133)
Deals (39768)
Drug Delivery (130)
Drug Development (91134)
Employer Resources (199)
FDA (18208)
Job Trends (17372)
News (396949)
Policy (39838)
Tag
Academia (3002)
Academic (2)
Accelerated approval (14)
Adcomms (33)
Allergies (109)
Alliances (56976)
ALS (123)
Alzheimer's disease (1613)
Antibody-drug conjugate (ADC) (192)
Approvals (18161)
Artificial intelligence (407)
Autoimmune disease (39)
Automation (20)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (139)
Biotechnology (482)
Bladder cancer (103)
Brain cancer (41)
Breast cancer (407)
Cancer (3201)
Cardiovascular disease (257)
Career advice (3542)
Career pathing (34)
CAR-T (213)
CDC (43)
Cell therapy (588)
Cervical cancer (25)
Clinical research (74475)
Collaboration (1151)
Company closure (3)
Compensation (733)
Complete response letters (38)
COVID-19 (2914)
CRISPR (70)
C-suite (386)
Cystic fibrosis (124)
Data (3247)
Decentralized trials (2)
Denatured (54)
Depression (83)
Diabetes (384)
Diagnostics (6994)
Digital health (26)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (192)
Drug pricing (155)
Drug shortages (36)
Duchenne muscular dystrophy (160)
Earnings (97783)
Editorial (50)
Employer branding (25)
Employer resources (169)
Events (131625)
Executive appointments (924)
FDA (20072)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1039)
Gene editing (152)
Generative AI (41)
Gene therapy (463)
GLP-1 (946)
Government (5284)
Grass and pollen (7)
Guidances (215)
Healthcare (20920)
HIV (46)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (194)
Immuno-oncology (13)
Indications (42)
Infectious disease (3119)
Inflammatory bowel disease (166)
Inflation Reduction Act (13)
Influenza (78)
Intellectual property (129)
Interviews (813)
IPO (17907)
IRA (57)
Job creations (5194)
Job search strategy (2863)
Kidney cancer (15)
Labor market (60)
Layoffs (601)
Leadership (27)
Legal (10138)
Liver cancer (85)
Longevity (12)
Lung cancer (448)
Lymphoma (224)
Machine learning (12)
Management (65)
Manufacturing (478)
MASH (104)
Medical device (14749)
Medtech (14755)
Mergers & acquisitions (22607)
Metabolic disorders (978)
Multiple sclerosis (107)
NASH (23)
Neurodegenerative disease (165)
Neuropsychiatric disorders (47)
Neuroscience (2407)
NextGen: Class of 2025 (7687)
Non-profit (5091)
Now hiring (51)
Obesity (497)
Opinion (292)
Ovarian cancer (106)
Pain (128)
Pancreatic cancer (133)
Parkinson's disease (203)
Partnered (25)
Patents (338)
Patient recruitment (186)
Peanut (55)
People (65789)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (22975)
Phase II (32336)
Phase III (24357)
Pipeline (1784)
Policy (252)
Postmarket research (3554)
Preclinical (10378)
Press Release (72)
Prostate cancer (156)
Psychedelics (46)
Radiopharmaceuticals (279)
Rare diseases (544)
Real estate (7402)
Recruiting (76)
Regulatory (27316)
Reports (62)
Research institute (2667)
Resumes & cover letters (650)
Rett syndrome (10)
RNA editing (12)
RSV (61)
Schizophrenia (104)
Series A (174)
Series B (120)
Service/supplier (30)
Sickle cell disease (69)
Special edition (22)
Spinal muscular atrophy (168)
Sponsored (37)
Startups (4307)
State (2)
Stomach cancer (17)
Supply chain (86)
Tariffs (71)
The Weekly (96)
Vaccines (937)
Venture capital (60)
Weight loss (334)
Women's health (52)
Worklife (20)
Date
Today (138)
Last 7 days (577)
Last 30 days (1984)
Last 365 days (33899)
2025 (19608)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1277)
Alabama (72)
Alaska (7)
Arizona (281)
Arkansas (14)
Asia (50593)
Australia (8892)
California (8001)
Canada (2480)
China (741)
Colorado (342)
Connecticut (356)
Delaware (215)
Europe (116123)
Florida (1195)
Georgia (273)
Hawaii (3)
Idaho (67)
Illinois (759)
India (34)
Indiana (396)
Iowa (19)
Japan (248)
Kansas (117)
Kentucky (33)
Louisiana (19)
Maine (73)
Maryland (1129)
Massachusetts (6126)
Michigan (280)
Minnesota (498)
Mississippi (4)
Missouri (107)
Montana (32)
Nebraska (26)
Nevada (86)
New Hampshire (74)
New Jersey (2246)
New Mexico (31)
New York (2234)
North Carolina (1267)
North Dakota (10)
Northern California (3470)
Ohio (259)
Oklahoma (17)
Oregon (48)
Pennsylvania (1714)
Puerto Rico (18)
Rhode Island (40)
South America (1654)
South Carolina (36)
South Dakota (1)
Southern California (2977)
Tennessee (132)
Texas (1237)
United States (30192)
Utah (233)
Virginia (220)
Washington D.C. (80)
Washington State (704)
West Virginia (4)
Wisconsin (87)
There are 854,069 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
FDA Issued Myeloma, Alzheimer’s Approvals in July but Rejected Two CGTs
The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla. Meanwhile, the regulator turned away a cell therapy for Duchenne muscular dystrophy and a gene therapy for the rare disease Sanfilippo syndrome.
July 31, 2025
·
10 min read
·
Tristan Manalac
Earnings
Future of BMS’ Cobenfy Still in Limbo After Phase III Fail
Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase III ARISE study, which earlier this year failed to demonstrate significant symptom improvement.
July 31, 2025
·
2 min read
·
Tristan Manalac
Earnings
Sanofi Confident Tariffs Will Have Limited Impact on Finances in 2025
For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.
July 31, 2025
·
2 min read
·
Nick Paul Taylor
Earnings
AbbVie Pats Own Back as Skyrizi and Rinvoq Rake in Billions
Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.
July 31, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
Biogen’s Leqembi Push Getting Easier as CEO Eyes Early-Stage Pipeline Restock
Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter earnings call. The partnered Alzheimer’s drug Leqembi saw sales climb 20% for the period.
July 31, 2025
·
4 min read
·
Annalee Armstrong
Layoffs
Moderna Slashes Global Workforce by 10% as $1.5B Cost Cuts Hit Home
The announced reduction of hundreds of staff came a day ahead of Moderna’s Q2 earnings report.
July 31, 2025
·
1 min read
·
Annalee Armstrong
Diabetes
Lilly’s Mounjaro ‘Good Enough’ in Cardio Trial, Will Seek Expanded Approval
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical significance in reducing major events such as cardiovascular death, heart attack and stroke.
July 31, 2025
·
2 min read
·
Heather McKenzie
Job Trends
Greener Pastures? 81% of Employed Biopharma Professionals Want New Jobs,
BioSpace
Finds
Employed biopharma professionals are highly likely to look for new jobs in the next 12 months, although not quite as likely as their unemployed counterparts, according to a
BioSpace
LinkedIn poll. Three recruitment experts discuss the findings and what’s driving job searches.
July 31, 2025
·
4 min read
·
Angela Gabriel
IN PARTNERSHIP WITH IQVIA
We Don’t Own Patient Data–We’re Just Babysitting It
In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the concerns and opportunities of patient data driving AI tasks with Louise Molloy, associate director medical information and pharmacovigilance.
July 31, 2025
·
1 min read
·
Lori Ellis
Immunology and inflammation
AbbVie Carves Out Niche for Rinvoq With ‘Impressive’ Alopecia Areata Data
Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a competitive edge over other JAK inhibitors in the space.
July 31, 2025
·
2 min read
·
Tristan Manalac
1 of 85,407
Next
